Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease

Clinical Rheumatology

Volumn 32, Issue 12, 2013, Pages 1767-1775

  Onat, Altan ^a,e   Can, Günay ^a   Örnek, Ender ^b   Altay, Servet ^c   Yüksel, Murat ^d   Ademoğlu, Evin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Etlik Ihtisas Education Hospital   (Turkey)

^c DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d DICLE UNIVERSITY   (Turkey)

^e Nisbetiye Cad 59/24   (Turkey)

Author keywords

Coronary heart disease risk; HDL dysfunction; Metabolic syndrome; Pro inflammatory state; Serum uric acid

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; COHORT STUDIES; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPERURICEMIA; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXYGEN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SMOKING; TRIGLYCERIDES; TURKEY; URIC ACID;

EID: 84890428013     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2339-7     Document Type: Article

References (36)

1. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Nat Acad Sci USA 78:6858-6862
2. Kanellis J, Kang DH (2005) Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 25:39-42
3. Neogi T, Ellison RC, Hunt S, Terkeltaub R, Felson DT, Zhang Y (2009) Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart study. J Rheumatol 36:378-384
4. Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63:102-110
5. Feig DI, Kang D-H, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811-1821
6. Okura T, Higaki J, Kurata M, Irita J, Miyoshi K, Yamazaki T, Japanese Coronary Artery Disease Study investigators et al (2009) Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) study. Circ J 73:885-891
7. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthrit Care Res 62:170-180
8. Kuo C-F, See L-C, Yu K-H, Chou I-J, Chiou M-J, Luo S-F (2013) Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology 52:127-134
9. Feig DI (2009) Uric acid - a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 18:526-530
10. Bergamini C, Cicoira M, Rossi A, Vassanelli C (2009) Oxidative stress and hyperuricemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11:444-452
11. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q et al (2002) Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991-F997
12. Kontush A, Chapman MJ (2008) Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 8:51-59
13. Onat A, Hergenç G, Dursunoǧlu D, Küçü kdurmaz Z, Bulur S, Can G (2008) Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: relation to sex hormone-binding globulin. Int J Biol Sci 4:208-214
14. Onat A, Hergenç G, Can G, Küçükdurmaz Z (2009) Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity 17:564-570
15. Onat A, Hergenç G, Bulur S, Uǧur M, Küçü kdurmaz Z, Can G (2010) The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 142:72-79
16. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G (2009) Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58:1393-1399
17. Onat A, Hergenç G (2011) Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60:499-512
18. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 165:285-292
19. Onat A (2001) Risk factors and cardiovascular disease in Turkey. Atherosclerosis 156:1-10
20. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, SarI İ et al (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19:1055-1062
21. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438
22. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G (2007) Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191:182-190
23. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167
24. Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. WHO, Geneva, pp 124-127
25. Luk AJ, Levin GP, Moore EE, Zhou X-H, Kestenbaum BR, Choi HK (2009) Allopurinol and mortality in hyperuricaemic patients. Rheumatology 48:804-806
26. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 71:600-607
27. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY et al (2006) Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54:2541-2549
28. Sharp DS, Burchfiel CM, Rodriguez BL, Sharrett AR, Sorlie PD, Marcovina SM (2000) Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int J Clin Lab Res 30:39-48
29. Park KH, Shin DG, Kim JR, Hong JH, Cho KH (2010) The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med 25:129-136
30. Onat A, Can G (2013) Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. [Epub ahead of print]
31. Emerging Risk Factors Collaboration (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA 302:412-423
32. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS et al (2005) Oxidized phospholipids, lipoprotein(a) lipoprotein, and coronary artery disease. N Engl J Med 353:46-57
33. Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S et al (2003) Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278:52841-52847
34. Van den Elzen P, Garg S, Léon L, Brigl M, Leadbetter EA, Gumperz JE et al (2005) Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437:906-910
35. Vaisar T, Mayer P, Nilsson E, Zhao X-Q, Knopp R, Prazen BJ (2010) HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 411:972-979
36. Lippi G, Montagnana M, Salvagno GL, Targher G, Guidi GC (2010) Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile. Clin Cardiol 33:E76-E80